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Rolf Gruetter, and Kim Quang Do
Background: Glutathione (GSH) is the major cellular redox-regulator and antioxidant. Redox-imbalance due to genetically impaired GSH
synthesis is among the risk factors for schizophrenia. Hereweused amousemodelwith chronic GSHdeficit inducedby knockout (KO) of the
key GSH-synthesizing enzyme, glutamate-cysteine ligase modulatory subunit (GCLM).
Methods: With high-resolution magnetic resonance spectroscopy at 14.1 T, we determined the neurochemical profile of GCLM-KO,
heterozygous, and wild-type mice in anterior cortex throughout development in a longitudinal study design.
Results: Chronic GSH deficit was accompanied by an elevation of glutamine (Gln), glutamate (Glu), Gln/Glu, N-acetylaspartate, myo-
Inositol, lactate, and alanine. Changes were predominantly present at prepubertal ages (postnatal days 20 and 30). Treatment with
N-acetylcysteine from gestation on normalized most neurochemical alterations to wild-type level.
Conclusions: Changes observed in GCLM-KO anterior cortex, notably the increase in Gln, Glu, and Gln/Glu, were similar to those reported
in early schizophrenia, emphasizing the link between redox imbalance and thedisease and validating themodel. The data also highlight the
prepubertal period as a sensitive time for redox-relatedneurochemical changes anddemonstrate beneficial effects of earlyN-acetylcysteine
treatment.Moreover, the data demonstrate the translational value ofmagnetic resonance spectroscopy to study brain disease in preclinical
models.
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O xidative stress and impaired redox-regulation occur in neu-rodegenerative diseases such as Parkinson’s (1), Alzhei-mer’s (2), and Huntington disease (3), as well as in psychiat-
ic pathologies including bipolar disorder (4) and schizophrenia (5).
hereas redox-dysregulation in neurodegenerative diseases is
ikely a downstreamconsequence of other primary causes, compel-
ing data suggest that redox-dysregulation is a primary risk factor
or schizophrenia (5). Indeed, glutathione (GSH), the major cellular
edox-regulator and antioxidant, is decreased in cerebrospinal
uid, medial prefrontal cortex (6,7) and postmortem striatum (8) of
chizophrenia patients. Furthermore, the two genes coding for the
ey GSH-synthesizing enzyme, glutamate-cysteine ligase catalytic
GCLC) and modifier (GCLM) subunits, are associated with schizo-
hrenia (9,10). Polymorphisms of trinucleotide repeats on theGCLC
ene are accompanied by reduced enzyme activity, decreasedGSH
evels, and higher risk for the disease (10). Moreover, the response
o an oxidative stress challenge in patient fibroblasts is depressed
10), indicating a deficit in GSH regulation. Thus, in combination
ith environmental insults that generate oxidative stress, this re-
ox dysregulation may play a central role in schizophrenia (5,11).
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doi:10.1016/j.biopsych.2011.07.035To investigate the link between redox imbalance and the
isease, we study mice with genetic deletion (knockout) of the
CLM gene (KO) (12), which display a sustained GSH deficit
ompared with wild-type mice (WT) (12,13). GCLM-KO mice ex-
ibit phenotypic anomalies that are similar to those observed in
atients: impaired parvalbumine (PV) immunoreactive fast-
piking (FS) gamma-aminobutyric acid (GABA)ergic interneu-
ons and oscillatory network activity in the ventral hippocampus
13) and anterior cingulate cortex (ACC) (14), deficits in myelina-
ion (15), and alterations in social and stress-related behaviors
14). These deficits are aggravated by additional oxidative stress
uring particular developmental periods (14). This is in line with
he notion that schizophrenia is a neurodevelopmental disease
nvolving progressive deterioration during childhood and ado-
escence (16,17).
Schizophrenia patients display brain neurochemical alterations,
s revealed by in vivo magnetic resonance spectroscopy (MRS). A
eta-analysis revealed consistently decreased N-acetylaspartate
NAA) concentrations across different brain regions (18). This find-
ng has received further support from recent studies in hippocam-
us (19), striatum (20,21), thalamus (22), and ACC (23). Others have
emonstrated increased NAA levels in hippocampus of chronic
atients (24) and prefrontal cortex of high-risk adolescents (21).
lterations are also frequently reported for glutamine (Gln), gluta-
ate (Glu), and Gln/Glu. Like the case for NAA, the direction of the
hanges is variable. Accordingly, increased levels of Gln, Glu, or
ln/Glu have been found in early stages of the disease (23,25–27),
hereas decreased levels have been observed in chronic patients
28,29). MRS can be applied both in clinical subjects and preclinical
nimal models. As such, it represents a methodology of choice for
ranslational approaches. Indeed, a recent preclinical MRS study
eported elevated Gln/Glu and altered brain glucose and lactate
etabolism in prefrontal cortex of rats with N-methyl-D-aspartate
eceptor (NMDAR) hypofunction (30), a model that mimics schizo-
hrenia symptoms (31,32).
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J.M. das Neves Duarte et al. BIOL PSYCHIATRY 2012;71:1006–1014 1007Here we used state-of-the-art high-resolution MRS at 14.1 T in a
preclinical setting to investigate noninvasively whether redox im-
balance induces neurochemical alterations in GCLM-KO anterior
cortex similar to those observed in patients. In contrast to most
clinical studies, which routinely quantify concentrations of only few
metabolites at one time point of the disease, wemeasured a profile
of 18 metabolites in a longitudinal study design (33). Thus, one
objectivewas to screen theGCLM-KOmouse brain at various stages
of development for relevant neurochemical changes to pinpoint
sensitive periods. Because GSH depletion in GCLM-KO mice was
associated with schizophrenia-relevant neurochemical alterations,
another objective was to test whether partially restoring the redox
balance in these animals with N-acetylcysteine (NAC) (34) would
normalize their neurochemical profile. NAC serves as precursor for
GSH synthesis (35) and exerts direct antioxidant effects (36). Given
to patients as adjunct to their antipsychotic therapy, NAC alleviates
negative symptoms, reduces side effects (37), and improves a pre-
attentional componentof the auditory evokedpotential onelectro-
encephalogram (38).
Methods andMaterials
Animals
GCLM-KO animals were generated (12) and kindly provided by
TP Dalton (Cincinnati University, Ohio). Mice used for this study
were bred and maintained in the local animal facility in a tempera-
ture- and humidity-controlled environment under a 12-h light–
dark cycle with free access to food andwater. All experiments were
performed in accordance with the Guide for the Care and Use of
Laboratory Animals (39) and were approved by the cantonal veteri-
nary office.
Design
The first experiment investigatedwhether the developing ante-
rior cortical neurochemical profile differed between GCLM geno-
types. A second experiment assessed whether NAC treatment
normalizes theobservedgenotypedifferences. To account for test–
retest reliability, a non-NAC-treated control group for each geno-
typewas included in the secondexperiment. This resulted inoverall
more non-NAC-treated versus NAC-treated animals. Respective an-
imal numbers are as follows: 27 GCLM-KO (17 nontreated; 10 NAC-
treated), 25 heterozygous (HZ; 19 nontreated; 6 NAC-treated), and
32WT (20nontreated; 12NAC-treated)mice. In both experiments, a
mixed cohort of male and female mice was used (the number of
males and females was balanced in each experimental group).
1H-Magnetic Resonance Spectroscopy
In vivo 1H-MRS has been implemented on clinical platforms to
allow the quantification of neurochemical profiles comprising 14
metabolites (40,41). It has also been validated for rodents to deter-
mine a profile of 20metabolites (42). Here, we quantified 18metab-
olites at postnatal Days (P)10, P20, P30, P60, and P90, using aDirect-
Drive spectrometer (Varian, Palo Alto, California) interfaced to an
actively shielded 14.1-Tmagnetwith a 26-cmhorizontal bore (Mag-
nex Scientific, Abingdon, United Kingdom) and a quadrature 1H
coil, as previously described (33). Briefly, field homogeneity was
achieved with FAST(EST)MAP (43,44) and spectra were acquired
using SPECIAL (45) with echo time of 2.8 msec, repetition time of 4
sec from the anterior cortex (voxel of interest at .62 rela-
tive to bregma; volume ranged from 2.5 to 3.8 L across ages) of
mice under isoflurane (Attane, Minrad, New York) anesthesia. Me-
tabolite concentrations were quantified with LCModel (Stephen
Provencher, Oakville, Canada) including a macromolecule spec-
trum in the database and scaling concentrations to correctedwater 1ontent asmeasured fromunsuppressedwater spectra (33). Effects
f repeated isoflurane anesthesia on the neurochemical profile and
n behavior were investigated previously and can be largely ruled
ut (33).
AC Treatment
NAC (Fluimucil, Zambon, Switzerland) was administered in
rinking water at 2.4 g/L (480 mg/kg NAC per adult animal; calcu-
ated based on an average water consumption of 5 mL/animal/day
nd average animal bodyweight of 25 g; comparable to Atkuri et al
34]) before and during mouse pregnancy and after birth through-
ut the experimental period. Fresh solutions were prepared every
ther day. Average daily drinking volume per adult animal was
ignificantly lower in NAC-treated animals across all three geno-
ypes (4.78mL SEM .19) comparedwith non-NAC-treated control
nimals (6.69 mL  SEM .27; p  .001; n  30) but was within the
ormal range compared with other studies (46).
lood GlutathioneMeasurements
To assess whether NAC consumed by the dam is transmitted to
er suckling pups, blood samples were collected from offspring of
AC-treated and non-NAC-treated dams at P10. Samples were also
ollected at P30, by which age animals drink NAC in water on their
wn. Increased blood GSH levels were taken as indirect measure of
NAC effect. Accordingly, GCLM-KO (P10 nontreated: n 6; NAC-
reated: n 5; P30 nontreated: n 8; NAC-treated: n 7) and WT
P10 nontreated: n  6; NAC-treated: n  4; P30 nontreated: n 
; NAC-treated: n  8) animals were decapitated. Trunk blood
as collected in ethylenediamine tetraacetate K3E microvettes
Sarstedt, Nuembrecht, Germany), shock frozen on dry ice, and
tored at 80° C. Total GSH concentration in whole blood was
etermined using a colorimetric assay from Calbiochem (EMD Bio-
ciences, Darmstadt, Germany), with a sensitivity of 5 mol/mL.
amples were analyzed in triplicates (intraassay variation coeffi-
ient of 3.42%; interassay variation coefficient of 3.58%).
tatistical Analysis
Amultiple regressionwasfitted for eachmetabolite at each time
oint to compare metabolite concentrations between the three
enotypes using R environment (The R project for Statistical Com-
uting); Bonferroni adjustment (for five time points) was applied to
ach comparison to avoid the inflation of Type I error. Animals’ sex
as controlled for in all regression models. Fit adequacy was as-
essed for eachmultiple regression (47). To test whether NAC treat-
ent had normalizing effects, metabolite concentrations of NAC-
reated KO and HZ animals were compared with non-NAC-treated
T animals at relevant timepoints (i.e., whenmetabolites hadbeen
ignificantly different fromWT in non-NAC-treated condition) with
wo-way analysis of variance (ANOVA) considering sex as the sec-
nd factor. The effect of NAC within genotypes was assessed for
ach metabolite and time point using two-way ANOVA (treat-
ent  gender) with Bonferroni adjustment for the five time
oints. To assesswhether bloodGSH levels differed between geno-
ypes, one-way ANOVA was performed for NAC- and non-NAC-
reated animals at P10 and P30 including samples of both genders.
ignificant genotype effects were followed up with independent-
ample t tests. Whether blood GSH levels were increased in NAC-
ersus non-NAC-treated WT and HZ animals at P10 was assessed
ith independent-sample t tests. Average drinking volume of non-
AC-treated versus NAC-treated animals was analyzed with an in-
ependent-sample t test including data of all genotypes and both
enders. The ANOVA and t tests were performed in PASW Statistics
8 (SPSS, Somers, New York).
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Spectra allowed quantifying a profile of 18 metabolites with
Cramer-Rao lowerbound (CRLB)below25%with fewexceptions for
metabolites that occur at lowconcentration in cortex. TheCRLBwas
above 25% for four measurements of N-acetylaspartylglutamate
between P20 and P60 (at maximum 48%) and of aspartate (Asp) at
P10 (at maximum 31%). GSH concentrations in the cortex of
GCLM-KO mice were very low and below the detection limit and
thus associated with high CRLB at all time points. As observed in
Figure 1, the neurochemical profile of all genotypes generally
changed as function of development (33).
Neurochemical Alterations inGCLM-KO and HZMice
GCLM-KO Mice. The analyses revealed age-specific neuro-
chemical alterations in GCLM-KO cortex relative to WT (Figure 1A
“nontreated”; summarized in Table 1). As expected, spectra of KO
mice showed substantially decreased GSH levels across all ages (at
least83% relative toWT [at P10;.7, t (47)7.6,p0.005].
This GSH deficit induced prominent neurochemical alterations at
prepubertal age P20 as exemplified in Figure 2A: an increase of
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Figure 1. Cortical neurochemical profile of nontreated control and N-acety
(KO) animals throughout development. Data are represented as mean  S
nontreated WT animals was included to facilitate visual evaluation of NAC
**GCLM-KO andWT (red) andGCLM-HZ andWT (green). *.005 p .05. p .005.
nontreated WT level for KO (red) and HZ (green) animals.
www.sobp.org/journalln [35%;  1.01, t (49) 4.09, p .005], Glu [12%;  1.05,
(49) 2.95, p .05], andGln/Glu [23%; .98, t (49) 3.08, p
05], as well as ofmyo-inositol [Ins;24%;  .5, t (49) 2.89, p
05] and NAA [14%;   .99, t (49) 3.38, p .05] relative to WT.
ln [34%;  .95, t (49) 2.74, p .05] and Gln/Glu [21%; 
65, t (49)  3.16, p  .05] remained elevated at P30. At adult age
90, the concentrations of lactate [Lac; 68%;   1.15, t (48) 
.04, p .005] and alanine [Ala;28%;  .3, t (48) 2.9, p .05]
ere increased. As shown in Figure 1B (“nontreated”), the other
etabolites remained unaffected by GSH deficit.
GCLM-HZMice. Compared withWT, the spectra of HZ animals
isplayed a slight reduction of cortical GSH concentration at most
evelopmental ages with a significant decrease at P60 [24%; 
.28, t (48)3.58, p .05]. This slight but consistent GSH deficit
as accompanied by an elevation of Gln [23%;   .74, t (49) 
.01,p .05] andadecrease inAla [24%;.34, t (49)2.73,
 .05] at P20. SeeFigure1A (“nontreated”; summarized inTable1).
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NAC Affects the Neurochemical Profile of All Genotypes.
ithin-genotype comparisons revealed NAC-induced neurochem-
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J.M. das Neves Duarte et al. BIOL PSYCHIATRY 2012;71:1006–1014 1009ical changes for all genotypes (Figure 1; summarized in Table 2).
hese changes were most prominent in WT, which showed in-
reased Ins (41%) and glycerophosphocholine/phosphocholine
GPC/PCho;65%)atP10, aswell as increasedascorbate (Asc; 21%),
la (24%), and taurine (Tau; 28%) and decreased Gln (32%)
andGln/Glu (47%) at P20. NAC-treatedHZmice only displayed an
increase in GPC/PCho (33%) at P90 compared to non-NAC-
treated HZ. In KOmice, NAC treatment decreased Gln (24%) con-
centrations at P20 and phosphoethanolamine (PE;47%) at P90 in
comparison to non-NAC-treated KO. See Table 2 for significance
levels.
NAC Has Normalizing Effects in GCLM-KO and HZ Animals.
Considering the previously identified neurochemical anomalies in
GCLM-KO and HZ animals relative toWT, we assessedwhether NAC
has normalizing effects. As indicated in Figure 1A (“NAC-treated”)
and Table 1, NAC treatment from gestation onward normalized the
concentrations of Gln, Glu, Gln/Glu, and Ins in young P20 KO ani-
mals, as well as the concentration of Ala in adult P90 KO animals to
non-NAC-treated WT level. In HZ animals, NAC treatment similarly
normalized Gln andAla levels at P20. GSH concentration at P60was
not statistically more different between NAC-treated HZ animals
and WT. Rather than being a NAC-induced normalization, we sug-
gest this was due to relatively high intersubject variability in the
NAC-treated group.
NACTreatmentof theDamIncreasesBloodGSH inPrewean-
ling WT and HZ Offspring. Table 3 summarizes data obtained
from whole-blood GSH measurements at P10 and P30. As in the
brain, GSH levels in the blood of KO (NAC- and nontreated) animals
were drastically decreased compared with WT and HZ at both P10
andP30. GSH concentrations in nontreatedHZanimalswere similar
to WT at both ages. Consistent with the developmental trend of
cortical GSH concentrations, blood GSH levels in nontreated ani-
mals strongly increased from P10 to P30. NAC treatment signifi-
cantly upregulated GSH levels inWT at P10 but not at P30. A similar
trend was present in HZ animals. Thus, NAC increased blood GSH
levels early on when endogenous GSH concentrations were still
relatively low. NAC treatment had no effect on blood GSH levels in
KO animals.
Discussion
Weused 1H-MRS at 14.1 T to determine the cortical neurochem-
ical profile ofGCLM-KO, HZ, andWTmice throughout development
and to investigate the effect of redox imbalance due to GSH deficit,
Table 1. Neurochemical Alterations in Anterior Cortex of GCLM-KO and HZ
P10 P20
HZ KO HZ KO
Glutathione 2283% 2283%
Glutamate 112%
Glutamine 123% 1135%
Gln/Glu 123%
N-Acetylaspartate 1 14%
Lactate
myo-Inositol 124%
Alanine 224%
This table summarizes significant differences between genotypes in th
shows which of these differences between genotypes were normalized to n
the direction of the neurochemical change (i.e., arrows pointing down indica
One arrow represents .005 p .05. Two arrows reflect p .005. Underlin
Gln, glutamine; Glu, glutamate; HZ, heterozygous; KO, knockout; NAC, Nwhich has been implicated in schizophrenia (5,11). The high resolu- wion and sensitivity of themethod allowed us to identify a profile of
edox-sensitive metabolites—namely, Gln, Glu, Gln/Glu, NAA, Ins,
ac, and Ala. The majority of these metabolites were altered in
oung KO animals during the prepubertal period (P20 and P30).
xceptions were Lac and Ala, which accumulated in the adult KO
ortex as a consequence of chronic GSH deficit. Long-term treat-
ent with NAC normalized most neurochemical alterations to WT
evel.
hronic GSH Deficit Induces Neurochemical Alterations in
nterior Cortex
ComparedwithWT,GCLM-KOmicedisplayed a severe and sustained
SH depletion in anterior cortex, which was accompanied by increased
oncentration of Glu, a neurochemical precursor of GSH. Notably, Glu
ccumulation is also observed in neuronal cultures treatedwith theGSH
ynthesis inhibitorL-buthionine-(S,R)-sulfoximine (BSO) (48).GCLenzyme
unction is impaired in both GCLM-KO and BSO-treated conditions. As a
esult, less Glu is incorporated into GSH and may accumulate, po-
entially leading to excitotoxicity (49) and impaired cell energy
etabolism (50). Increased Glu levels are consistent with the
MDAR hypofunction theory of schizophrenia (51). NMDARs are
rucial to control the normal firing rate of FS interneurons (52).
MDAR hypo-function renders FS interneurons less excitable, re-
ulting in persistent disinhibition of pyramidal neurons and in-
reasedextracellularGlu. Interestingly, PV FS interneurons are func-
ionally impaired in ACC of GCLM-KO mice (5,53). Whether this PV
nterneuron impairment is associated with NMDAR hypofunction
emains unclear. High Glu levels in theGCLM-KO anterior cortex are
lso in line with the recently reported antipsychotic efficacy of
gonists for the mGluR-2 receptors, which inhibit neuronal Glu
elease at high extracellular Glu concentration (54,55).
The GCLM-KO anterior cortex was furthermore characterized by
levated Gln and Gln/Glu. Together with increased Glu, these neu-
ochemical alterationsmay reflect differences in number ormetab-
lism of specific cell types within this region compared with WT.
hus, future studies will need to clarify whether PV deficit in
CLM-KO ACC (5,53) is associated with a loss of PV FS interneurons.
levated Gln/Glu could also be a consequence of increased extra-
ellular synaptic Glu concentration, which stimulates the Glu–Gln
ycle. Accordingly, it has been reported that Gln synthesis is poten-
iated in response to high extracellular Glu via a functional coupling
etween the glutamate transporter EAAT2 and glutamine synth-
se (56).
Increased concentrations of Gln, Glu, andGln/Glu are consistent
Relative to WT and the Effect of NAC
P30 P60 P90
HZ KO HZ KO HZ KO
2285% 224% 2288% 2295%
134%
121%
1168%
128%
rochemical profile of KO and HZ animals compared with WT. Moreover, it
AC-treatedWT level in response to chronic NAC treatment. Arrows indicate
at thismetabolite concentration is decreased relative toWT and vice versa).
ects were normalized by NAC treatment to nontreated WT levels.
ylcysteine; P, postnatal day; WT, wild type.Mice
e neu
on-N
te th
ed effith clinical MRS data from early stages of schizophrenia. Accord-
www.sobp.org/journal
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(25) and other studies with first-episode drug-naive (26) or mini-
mally treated patients (23) reported increased Gln, Glu, or Gln/Glu.
In contrast, studies with chronic patients frequently report a de-
crease in the concentrations of these metabolites (28,29). This sug-
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Figure 2. (A) Representative in vivo 1H-MRS spectra acquired at 14.1 T from
he anterior cortex of wild type (WT) and knockout (KO) mice at postnatal
ay (P) 20. Most prominent alterations induced by glutathione (GSH) deple-
ion were observed at this age and are evidenced by the difference spec-
rum—namely, increased NAA, Glu, Gln, Ins, and Cre concentrations. The
ost intense resonance of GSH at 3.77 ppm overlaps with Glu and Gln,
asking the decrease of the GSH peak. For resolution enhancement, a
hiftedGaussian function (gf .12 andgsf .05)was appliedbefore Fourier
transformation. (B) Fit of the 1H-MRS spectrum from the anterior cortex of a
P20mouse anterior cortex. The LCModel fit line is shown in red over the raw
spectrum. A decomposition of the fit line in spectra of the individualmetab-
olites is shownbelow, notably also for GSH. Ala, alanine; Asc, ascorbate; Asp,
aspartate; Cr, creatine; GABA, 	-aminobutyrate; Gln, glutamine; Glu, gluta-
mate; GSH, glutathione; Gly, glycine; GPC, glycerophosphocholine; Lac, lac-
tate; Ins, myo-inositol; Mac, macromolecule baseline; NAA, N-acetylaspar-
tate; NAAG, N-acetylaspartylglutamate; PE, phosphoethanolamine; PCho,
phosphocholine; PCr, phosphocreatine; Tau, taurine.gests that chronic illness andmedication lead to a gradual progres- a
www.sobp.org/journalion of neurochemical changes and that increased Gln, Glu, and
ln/Glu may serve as metabolic markers for the early disease state.
The anterior cortex of GCLM-KO mice also displayed increased
AA concentration. Changes in NAA concentration are observed in
rains of schizophrenia patients across various regions. However, in
ontrast to our results, patient studies generally point toward de-
reased concentrations (18). It should be noted, however, that this
ecrease in NAA concentration is subtle and requires large sample
izes to be detected, which may be related to considerable hetero-
eneity among schizophrenia patients. Indeed, few studies have
eported an elevation of NAA levels in the hippocampus of schizo-
hrenia patients (23) and in prefrontal cortex of adolescents at high
enetic risk (21). Our results are thus in line with a general NAA
athology in patients. In GCLM-KO mice, increased NAA levels are
resent at prepubertal age, which has so far not been studied in
linical settings. The prepubertal period around P20 is character-
zed by a high rate of myelination (57,58). NAA accumulation in
CLM-KO mice may, therefore, reflect reduced deacetylation by
ligodendrocytes, which is essential for the synthesis of myelin
ipids (59). Impaired cortical myelination is in agreement with re-
uced immunoreactivity of myelin basic protein in GCLM-KO ACC
ompared with WT (15). Interestingly, gene expression profiling,
eurocytochemical, and neuroimaging studies also strongly sug-
est compromised myelination in schizophrenia (60,61). The in-
rease in Ins levels at the same age, P20, may reflect a reduction in
ynthesis of phospholipids, its incorporation into lipidmembranes,
r both (62,63). Altered Ins concentration has been observed in the
rain of schizophrenia patients (28,64) and has been linked to cog-
itive impairment in several neurological disorders (65–67).
At P90, chronic GSH deficit in KO animals resulted in a drastic
ccumulation of cortical Lac and increased Ala concentration,
hich may be related to altered glucose metabolism and mito-
hondrial dysfunction. Indeed, it has been demonstrated that oxi-
ative stress diminishes mitochondrial oxidative phosphorylation
nd activity of the citric acid cycle enzyme alpha-ketoglutarate
ehydrogenase (68), which can contribute to both Lac accumula-
ion and increased Glu. The fact that Lac and Ala accumulate in
dult KO but not in HZ animals, which experience only a transient
SH deficit, suggests that accumulation of bothmetabolites marks
he long-term consequences of chronic GSH deficiency. Clinical
tudies reveal discrepant Lac andAla changes in patients’ postmor-
em brain tissue (69–71), cerebrospinal fluid (72,73) and plasma
74). Because these two metabolites have not been quantified in pa-
ients with in vivo MRS, it remains unclear how our results relate to
atient cortical neurochemical data. We propose that the concentra-
ionsof Lac andAla in thepatient brainmay serve as important indica-
ors for long-term redox-related changes in future in vivoMRS studies.
eurochemical Alterations inGCLM-KOMice Occur Primarily
t Prepubertal Ages
Prominent neurochemical alterations in GCLM-KO mice at pre-
ubertal ages P20 and P30 suggest high GSH demand during this
eriod. At this age, cerebralmetabolismmustmeet energy require-
ents tomaintain the high rate of cellular differentiation, myelina-
ion, synapse formation, and axon- and dendrite-sprouting (75).
eneration of reactive oxygen species increases concomitantly.
he relative lack of GSH to neutralize these reactive oxygen species
eads to altered metabolism and cell injury—namely, in mitochon-
ria. Interestingly, metabolites such as Gln, Glu, Gln/Glu, Ins, and
AA with concentrations that were changed during the prepuber-
al period were expressed at normal levels in adulthood. This may
e related to a smaller GSH demand at adult ages. In addition, KO
nimals may develop adaptational or compensatory mechanisms
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but not all deficits, as evidenced by late Lac and Ala accumulation.
Effects of NAC Treatment on GSH Levels
Chronic NAC treatment increased GSH levels in the blood of WT
offspring at P10whenpupsweredrinking thedam’smilk, but not at
P30. This indicates for the first time that NAC effects can be trans-
mitted via the dam’s milk. The fact that NAC increased blood GSH
levels at P10 but not P30 may indicate that the early postnatal
period is characterizedby a relative lack of cysteine (Cys) availability
comparedwith later ages. This is in accordancewith the rise of GSH
levels from P10 to 30 in nontreated animals of all genotypes. In
addition, this age-dependent NAC effect could be related to amat-
urational change in the GSH inhibitory feedback control (35). The
lood (and brain) of GCLM-KO mice showed no NAC-induced in-
rease in GSH levels. This was expected because the GSH synthesiz-
ng enzyme GCL is hypofunctional in these animals (12).
In contrast to blood, there was no detectable NAC-induced in-
crease of GSH in WT cortex. It has been demonstrated that NAC or
NAC-derivedCys crosses theblood–brainbarrier (76) toboostbrain
GSH levels duringperiods of increasedoxidative stress (76,77). Here
we quantified cortical GSH levels upon NAC treatment at resting
state rather than under increased stress condition. Because brain
GSH levels are tightly regulated by a feedback inhibition system
(35), NAC-induced rise in GSH levels were likely subtle and thus
difficult to capture in cortex.
NAC Treatment Normalizes Early Neurochemical Alterations
inGCLM-HZ and KOMice
NAC crosses the placental barrier (78) and is transmitted via the
dam’s milk, suggesting that offspring of treated females benefited
Table 2. Within Genotype Effects of NAC Treatment on Metabolite Concen
P10 P20
WT HZ KO WT HZ
scorbate 121%
lutamine 232% 2
ln/Glu 247%
hosphoethanolamine
PC/PCho 165%
lanine 124%
yo-Inositol 141%
aurine 1128%
This table summarizes significant NAC-induced metabolite changes rela
irection of the NAC-induced change (i.e., arrows pointing down indicate th
nd vice versa). One arrow represents .005 p .05. Two arrows reflect p
20. P30 is characterized by a relative lack of NAC effects.
Gln, glutamine; Glu, glutamate; GPC/PCho, glycerophosphocholine/phos
ge; WT, wild type.
able 3. GSH Levels in Whole Blood
P10
Nontreated mol/mL NAC-Treated mol
WT .37  .06 .73  .03bb
HZ .37  .07 .49  .08
KO .12  .02aa .14  .07aa
Mean GSH concentrations SEM are shown for each group. One supers
GSH, glutathione; HZ, heterozygous; KO, knockout; NAC, N-acetylcystein
aSignificant difference of GSH concentrations with respect to WT.
bSignificant increase in GSH concentration under NAC treatment.
cSignificant difference in GSH concentration of nonNAC-treated animals betwrom NAC effects throughout the gestational and early postnatal pe-
iod. Accordingly, NAC treatment normalizedmost neurochemical al-
erations in KO and HZ animals at P20. Clear examples of normalized
etabolites are Gln, Glu, Gln/Glu, NAA, and Ins. KO animals also prof-
ted from NAC treatment at adult age, as indicated by the normaliza-
ionofAla at P90. Clinical studies show thatNACas adjunct to antipsy-
hotic medication increases blood GSH levels and improves negative
ymptoms and medication side effects (37,38). This is the first report
hat chronicNAC treatment normalizes cortical neurochemical abnor-
alities in a preclinical schizophreniamodel.
How can NAC exert normalizing effects in GCLM-KO mice when
AC-derived Cys cannot be incorporated into GSH? A recent study
emonstrates that NAC-derived Cys can enter an alternative redox
ystem through which it exerts direct antioxidant and redox-
egulatory actions (36). Specifically, Cys together with its oxidized
ormcystine (Cys)2 enters the (Cys)2/Cys redox cycle,which is driven
y the (Cys)2/Glu antiporter (system xc
) (36). Interestingly, system
c
 has also been proposed to be an important mediator for the
fficacy of NAC in improving negative symptoms in patients (37).
pecifically, it has been proposed that NAC-derived Cys activates
ystem xc
, resulting in high extracellular Glu, which then activates
xtrasynaptic mGluR-2 receptors and leads eventually to less Glu
elease from pyramidal neurons (55). Thus, in GCLM-KO mice, NAC
ormalization may be mediated in part by system xc
 either
hroughactivationofmGluRsor through the (Cys)2/Cys redox cycle,
hich can compensate part of the GSH deficit.
reatment with NAC Induces Changes in the Neurochemical
rofile of AllGCLMGenotypes
Within-genotype analyses revealed that NAC treatment modi-
ed the cortical neurochemical profile of all genotypes, including
ns
P30 P60 P90
WT HZ KO WT HZ KO WT HZ KO
247%
133%
o nonNAC-treated controls within the same genotype. Arrows indicate the
C reduced the metabolite concentration in animals of the same genotype
Note thatmost NAC-induced changes occur at early postnatal ages P10 and
holine; HZ, heterozygous; KO, knockout; NAC,N-acetylcysteine; P, postnatal
P30
Nontreated mol/mL NAC-Treated mol/mL
.74  .07cc .62  .08
.78  .05cc .69  .05
.38  .08aa,c .28  .07aa
letter represents .005 p .05. Two identical letters reflect p .005.
ostnatal age; WT, wild type.tratio
KO
24%
tive t
at NA
.005.
phoc/mL
cript
e; P, peen P10 and P30.
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treatment effects in human subjects, particularly in young at-risk
individuals who are not yet diagnosed with schizophrenia. NAC
effects in WT occurred especially at early ages P10 and P20.
Increased concentrations of Ala and Tau and the pronounced
decrease of Gln and Gln/Glu suggest stimulation of glycolysis
under NAC treatment (68). The pronounced increase in Tau dur-
ing early development reflects conversion of NAC-derived cys-
teine to Tau (79).
Conclusion
Our data corroborate the role of oxidative stress and redox dys-
regulation in the development of schizophrenia and add to the
validity of the GCLM-KOmousemodel. Moreover, our data suggest
that theprepubertal period is particularly sensitive to redox-related
neurochemical changes, highlighting the importance of earlymon-
itoringand intervention.Wesuggest that anelevationofGln,Glu, or
Gln/Glu as observed in brains of early schizophrenia patients may
already be present at prepubertal age and may thus qualify as
potential early biomarker for schizophrenia in the future. NACmay
be a promising candidate for early treatment intervention. Finally,
our data highlight the translational value of MRS. This technique
has been implemented on clinical platforms to allow the quantifi-
cation of neurochemical profiles comprising 14 metabolites. Here
we show that the same technique can be reliably applied in a
preclinical schizophrenia model to quantify the same 14 (plus 4)
metabolites. This opens up new avenues for future translational
research.
This work was supported by the Centre d’Imagerie BioMédicale of
the University of Lausanne, University of Geneva, University Hospital
Geneva, University Hospital Lausanne, Ecole Polytechnique Federale
Lausanne, and the Leenaards and Jeantet Foundations; the Swiss Na-
tional Science Foundation (Grant No. 310030-135736 to KQD) and
Loterie Romande.
We thank the National Center of Competence in Research (NCCR)
“SYNAPSY—The Synaptic Bases of Mental Diseases.” We are also gra-
teful to Adeline Cottier and HélèneMoser for technical assistance.
The authors report no biomedical financial interests or potential
conflicts of interest.
1. Cookson MR, Bandmann O (2010): Parkinson’s disease: Insights from
pathways. HumMol Genet 19(R1): R21–27.
2. AgostinhoP, Cunha RA,Oliveira C (2010): Neuroinflammation, oxidative
stress and the pathogenesis of Alzheimer’s disease. Curr Pharm Des
16:2766–2778.
3. Turner C, Schapira AH (2010): Mitochondrial matters of the brain: The
role in Huntington’s disease. J Bioenerg Biomembr 42:193–198.
4. Steckert AV, Valvassori SS, Moretti M, Dal-Pizzol F, Quevedo J (2010):
Role of oxidative stress in the pathophysiology of bipolar disorder.
Neurochem Res 35:1295–1301.
5. Do KQ, Cabungcal J-H, Frank A, Steullet P, Cuenod M (2009): Redox
dysregulation, neurodevelopment, and schizophrenia.CurrOpinNeuro-
biol 19:220–230.
6. DoKQ, TrabesingerAH, Kirsten-KrügerM, Lauer CJ, DydakU,Hell D, et al.
(2000): Schizophrenia: Glutathione deficit in cerebrospinal fluid and
prefrontal cortex in vivo. Eur J Neurosci 12:3721–3728.
7. Matsuzawa D, Hashimoto K (2011): Magnetic resonance spectroscopy
studies of the antioxidant system in schizophrenia. Antioxid Redox Sig-
nal 15:2057–2065.
8. Yao JK, Leonard S, Reddy R (2006): Altered glutathione redox state in
schizophrenia. Dis Markers 22:83–93.
9. Tosic M, Ott J, Barral S, Bovet P, Deppen P, Gheorgita F, et al. (2006):
Schizophrenia and oxidative stress: Glutamate cysteine ligase modifier
as a susceptibility gene. Am J Hum Genet 79:586–592.
www.sobp.org/journal0. Gysin R, Kraftsik R, Sandell J, Bovet P, Chappuis C, Conus P, et al. (2007):
Impaired glutathione synthesis in schizophrenia: Convergent genetic
and functional evidence. Proc Natl Acad Sci U S A 104:16621–16626.
1. Yao JK, Reddy R (2011): Oxidative stress in schizophrenia: Pathogenetic
and therapeutic implications. Antioxid Redox Signal 15:1999–2002.
2. Yang Y, Dieter MZ, Chen Y, Shertzer HG, Nebert DW, Dalton TP (2002):
Initial characterization of the glutamate-cysteine ligase modifier sub-
unit Gclm(/) knockout mouse: Novel model system for a severely
compromised oxidative stress response. J Biol Chem 277:49446–49452.
3. Steullet P, Cabungcal J-H, Kulak A, Kraftsik R, Chen Y, Dalton TP, et al
(2010): Redox dysregulation affects the ventral but not dorsal hip-
pocampus: Impairment of parvalbumin neurons, gamma oscillation,
and related behaviours. J Neurosci 30:2547–2558.
4. Do KQ, Steullet P, Conus P, Kulak A, Cuenod M, Cabungcal J-H (2010):
Reverse translational approach to redox dysregulation in schizophre-
nia: Genetics, environment, neurodevelopment and therapy. Biol Psy-
chiatry 67(suppl):199.
5. Monin A, Klaey M, Butticaz C, Cabungcal JH, Steullet P, Do KQ (2011):
Redox dysregulation affects proliferation, differentiation of oligoden-
drocyte progenitors and myelination: Relevance for Schizophrenia Ab-
stract at the Viewer/Itinerary Planner, 41th Annual Meeting of the Soci-
ety for Neuroscience, Washington, DC.
6. Lewis DA, Levitt P (2002): Schizophrenia as a disorder of neurodevelop-
ment. Annu Rev Neurosci 25:409–432.
7. Rapoport JL, Gogtay N (2010): Childhood onset schizophrenia: Support
for a progressive neurodevelopmental disorder. Int J Dev Neurosci 29:
251–258.
8. Steen RG, Hamer RM, Lieberman JA (2005): Measurements of brain
metabolites by 1H magnetic resonance spectroscopy in patients with
schizophrenia: A systematic review andmethanalysis.Neuropsychology
30:1949–1962.
9. Klär AA, BallmaierM, Leopold K, Häke I, SchaeferM, Brühl R, et al. (2010):
Interaction of hippocampal volume and N-acetylaspartate concentra-
tion deficits in schizophrenia: A combinedMRI and 1H-MRS study. Neu-
roimage 53:51–57.
0. Goto N, Yoshimura R, Kakeda S, Moriya J, Hayashi K, Ikenouchi-Sugita A,
et al. (2011): Comparison of brain N-acetylaspartate levels and serum
brain-derived neurotrophic factor (BDNF) levels between patients with
first-episode schizophrenia psychosis and healthy controls. Eur Psychia-
try 26:57–63.
1. KeshavanMS, Dick RM, Diwadkar VA, Montrose DM, Prasad KM, Stanley
JA (2009): Striatal metabolic alterations in non-psychotic adolescent
offspring at risk for schizophrenia: A (1)H spectroscopy study. Schizophr
Res 115:88–93.
2. YooSY, YeonS,ChoiC-H, KangD-H, Lee J-M, ShinNY, et al. (2009): Proton
magnetic resonance spectroscopy in subjects with high genetic risk of
schizophrenia: Investigation of anterior cingulated, dorsolateral pre-
frontal cortex and thalamus. Schizophr Res 111:86–93.
3. Bustillo JR, Rowland LM,Mullins P, Jung R, ChenH, Qualls C, et al. (2009):
1H-MRS at 4 Tesla in minimally treated early schizophrenia. Mol Psychi-
atry 15:629–636.
4. Lutkenhoff ES, van Erp TG, Thomas MA, Therman S, Manninen M, Hut-
tunen MO, et al. (2008): Proton MRS in twin pairs discordant for schizo-
phrenia.Mol Psychiatry 15:308–318.
5. Tibbo P, Hanstock C, Valiakalayil A, Allen P (2004): 3-T proton MRS
investigation of glutamate and glutamine in adolescents at high ge-
netic risk for schizophrenia. Am J Psychiatry 161:1116–1118.
6. Hashimoto K, Engberg G, Shimizu E, NordinC, Lindström LH, Iyo M
(2005): Elevatedglutamine/glutamate ratio in cerebrospinal fluidof first
episode and drug naïve schizophrenic patients. BMC Psychiatry 5:6.
7. de la Fuente-Sandoval C, León-Ortiz P, Favila R, Stephano S, Mamo D,
Ramírez-Bermúdez J, et al. (2011): Higher levels of glutamate in the
associative-striatum of subjects with prodromal symptoms of schizo-
phrenia andpatientswith first-episodepsychosis.Neuropsychopharma-
cology 36:1781–1791.
8. Tayoshi SY, Sumitani S, Taniguchi K, Shibuya-Tayoshi S, Numata S, Iga J,
et al. (2009): Metabolite changes and gender differences in schizophre-
nia using 3-Tesla proton magnetic resonance spectroscopy (1H-MRS).
Schizophr Res 108:69–77.
9. Ohrmann P, Siegmund A, Suslow T, Spitzbergs K, Kersting K, Rother-
mundtM, et al. (2005) Evidence for glutamatergic neuronal dysfunction
in the prefrontal cortex in chronic but not first-episode patients with
33
3
3
4
4
4
5
5
5
5
5
5
5
6
6
6
6
6
6
6
6
6
6
7
7
7
7
J.M. das Neves Duarte et al. BIOL PSYCHIATRY 2012;71:1006–1014 1013schizophrenia: A proton magnetic resonance spectroscopy study.
Schizophr Res 73:153–157.
30. Iltis I, Koski DM, Eberly LE, Nelson CD, Deelchand DK, Valette J, et al.
(2009): Neurochemical changes in the rat prefrontal cortex following
acute phencyclidine treatment: An in vivo localized 1HMRS study. NMR
Biomed 22:737–744.
31. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney ER, Bremner JD, et
al. (1994): Subanesthetic effects of the noncompetitive NMDA antago-
nist, ketamine, in humans, Psychomimetic, perceptual, cognitive, and
neuroendocrine responses. Arch Gen Psychiatry 51:199–214.
32. Kantrowitz JT, Javitt DC (2010): Thinking glutamatergically: Changing
concepts of schizophrenia based upon changing neurochemical mod-
els. Clin Schizophr Relat Psychoses 4:189–200.
33. Kulak A, Duarte JMN, Do KQ, Grütter R (2010): Neurochemical profile of
the developing mouse cortex determined by in vivo 1H NMR spectros-
copy at 14 T and the effect of recurrent anesthaesia. J Neurochem 115:
1466–1477.
4. Atkuri KR, Mantovani JJ, Herzenberg LA, Herzenberg LA (2007): N-Ace-
tylcysteine—A safe antidote for cysteine/glutathione deficiency. Curr
Opin Pharmacol 7:355–359.
5. Meister A (1995): Glutathione biosynthesis and its inhibition. Methods
Enzymol 252:26–30.
6. Mandal PK, Seiler A, Perisic T, Kölle P, Banjac Canak A, Förster H, et al.
(2010): System x(c)- and thioredoxin reductase 1 cooperatively rescue
glutathione deficiency. J Biol Chem 285(29): 22244–53.
37. Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, et al. (2008):
N-acetyl cysteine as a glutathione precursor for schizophrenia—a dou-
ble-blind, randomized, placebo-controlled trial. Biol Psychiatry 64:361–
368.
38. Lavoie S, Murray MM, Deppen P, Knyazeva MG, Berk M, Bovet P, et al.
(2008): Glutathione precursor, N-acetyl-cysteine, improves mismatch
negativity in schizophrenia patients. Neuropsychopharmacology 33:
2187–2199.
9. Hedrich H, Bullock G, Petrusz P (2008): The Handbook of Experimental
Animals: The Laboratory Mouse. Oxford, England: Academic Press.
0. Mekle R, Mlynárik V, Gambarota G, Hergt M, Krueger G, Gruetter R
(2009): MR spectroscopy of the human brain with enhanced signal
intensity at ultrashort echo times on a clinical platform at 3T and 7T.
Magn ResonMed 61:1279–1285.
1. GambarotaG,Mekle R, Xin L, HergtM, vander ZwaagW, KruegerG, et al.
(2008): In vivomeasurement of glycine with short echo-time 1HMRS in
human brain at 7 T.MAGMA 22:1–4.
2. Pfeuffer J, Tkác I, Provencher SW, Gruetter R (1999): Toward an in vivo
neurochemical profile: Quantification of 18 metabolites in short-echo-
time (1)H NMR spectra of the rat brain. J Magn Reson141:104–120.
43. Gruetter R (1993): Automatic, localized in vivo adjustment of all first-
and second-order shim coils.Magn Reson Med 29:804–811.
44. Gruetter R, Tkácˇ I (2000): Field mapping without reference scan using
asymmetric echo-planar techniques.Magn Reson Med 43:319–323.
45. Mlynárik V, Gambarota G, Frenkel H, Gruetter R (2006): Localized short-
echo-time proton MR spectroscopy with full signal-intensity acquisi-
tion.Magn Reson Med 56:965–970.
46. Bachmanov AA, Reed DR, Beauchamp GK, Tordoff MG (2002): Food
intake, water intake, and drinking spout side preference of 28 mouse
strains. Behav Genet 32:435–443.
47. Montgomery DC, Peck EA, Vining GG (2006): Introduction to Linear Re-
gression Analysis, 4th edition. Chichester, England.
48. KogaM,MessmerM, SawaA, Snyderr SH, Sedlak TW (2010): Glutathione
un-GLU-ed: A role for glutathione in neuronal glutamate metabolism.
Abstract 225.6 Viewer/Itinerary Planner, Society for Neuroscience, San
Diego, California.
49. Miao Y, Qiu Y, Lin Y,Miao Z, Zhang J, Lu X (2010): Protection by pyruvate
against glutamate neurotoxicity ismediated by astrocytes through glu-
tathione-dependent mechanism.Mol Biol Rep 38:3235–3242.
50. Hertz J (2006): Glutamate, a neurotransmitter—and so much more. A
synopsis of Wierzba III. Neurochem Int 48:416–425.
51. Kantrowitz JT, Javitt DC (2010): N-methyl-d-aspartate (NMDA) receptor
dysfunctionordysregulation: Thefinal commonpathwayon the road to
schizophrenia? Brain Res Bull 83:108–121.
52. HomayounH,MoghaddamB (2007): NMDA receptor hypofunctionpro-
duces opposite effects onprefrontal cortex interneurons andpyramidal
neurons. J Neurosci 27:11496–11500.3. Cuenod M, Cabungcal J-H, Kulak A, Steullet P, Do KQ (2011): Redox
dysregulation andoxidative stress affect parvalbumin interneurons and
neural synchrony in anterior cingulated cortex during neurodevelop-
ment. Schizophr Bull 37(suppl 1):102.
4. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, et al.
(2007): Activation of mGlu2/3 receptors as a new approach to treat
schizophrenia: A randomized Phase 2 clinical trial. Nat Med 13:1102–
1107.
5. Krystal JH (2008): Capitalizing on extrasynaptic glutamate neurotrans-
mission to treat antipsychotic-resistant symptoms in schizophrenia [re-
view]. Biol Psychiatry 64:358–360.
6. Torres GE, Pena K, Quiroz M, Amara SG, Underhill SM (2010): Functional
coupling between the glutamate transporter EAAT2 and glutamine
synthetase. Abstract 544.13 Viewer/Itinerary Planner, 40th Annual
Meeting of the Society for Neuroscience, San Diego, California.
7. Costantino-Ceccarini E, Morell P (1972): Biosynthesis of brain sphingo-
lipids and myelin accumulation in the mouse. Lipids 7:656–659.
8. Muse ED, Jurevics H, Toews AD,MatsushimaGK,Morell P (2001): Param-
eters related to lipid metabolism as markers of myelination in mouse
brain. J Neurochem 76:77–86.
9. Kirmani BF, Jacobowitz DM, Kallarakal AT, Namboodiri MA (2002): As-
partoacylase is restricted primarily to myelin synthesizing cells in the
CNS: Therapeutic implications for Canavan disease. Brain Res Mol Brain
Res 107:176–182.
0. Höistad M, Segal D, Takahashi N, Sakurai T, Buxbaum JG, Hof PR (2009):
Linking white and grey matter in schizophrenia: Oligodendrocyte and
neuron pathology in the prefrontal cortex. Front Neuroanat 3:9.
1. Smith J, Ladi E, Mayer-Proschel M, Noble M (2000): Redox state is a
central modulator of the balance between self-renewal and differenti-
ation in a dividing glial precursor cell. Proc Natl Acad Sci U S A 97:10032–
10037.
2. Yao J, Stanley JA, Reddy RD, Keshavan MS, Pettegrew JW (2002): Corre-
lations between peripheral polyunsaturated fatty acid content and in
vivo membrane phospholipid metabolites. Biol Psychiatry 52:823–830.
3. Pettegrew JW, KeshavanMS, PanachalingamK, Strychor S, KaplanDB, et
al. (1991): Alterations in brain high-energy phosphate and membrane
phospholipidmetabolism in first-episode, drug-naïve schizophrenics: A
pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31
nuclear magnetic resonance spectroscopy. Arch Gen Psychiatry 48:563–
568.
4. Bustillo JR, Chen H, Gasparovic C, Mullins P, Caprihan A, Qualls C, et al.
(2011): Glutamate as a marker of cognitive function in schizophrenia: A
proton spectroscopic imaging study at 4 Tesla. Biol Psychiatry 69:19–27.
5. Chang L, Ernst T, Witt MD, Ames N, Gaiefsky M, Miller E (2002): Relation-
ships among brain metabolites, cognitive function, and viral loads in
antiretroviral-naïve HIV patients. Neuroimage 17:1638–1648.
6. Chantal S, Labelle M, Bouchard RW, Braun CM, Boulanger Y (2002):
Correlation of regional protonmagnetic resonance spectroscopic met-
abolic changes with cognitive deficits in mild Alzheimer disease. Arch
Neurol 59:955–962.
7. Parnetti L, Tarducci R, Presciutti O, Lowenthal DT, PippiM, PalumboB, et
al. (1997): Proton magnetic resonance spectroscopy can differentiate
Alzheimer’s disease from normal aging.Mech Ageing Dev 97:9–14.
8. McLain AL, Szweda PA, Szweda LI (2011): 
-ketoglutarate dehydroge-
nase: A mitochondrial redox sensor. Free Radic Res 45:29–36.
9. Halim ND, Lipska BK, Hyde TM, Deep-Soboslay A, Saylor EM, Herman
MM, et al. (2008): Increased lactate levels and reduced pH in postmor-
tem brains of schizophrenics: Medication confounds. J Neurosci Meth-
ods 169:208–213.
0. Beasley CL, Dwork AJ, Rosoklija G, Mann J, Mancevski B, Jakovski Z, et al.
(2009):Metabolic abnormalities in fronto-striatal-thalamicwhitematter
tracts in schizophrenia. Schizo Res 109:159–166.
1. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, Griffin JL, et
al. (2004): Mitochondrial dysfunction in schizophrenia: Evidence for
compromised brain metabolism and oxidative stress. Mol Psychiatry
9:684–97, 643.
2. Regenold WT, Phatak P, Marano CM, Sassan A, Conley RR, Kling MA
(2009): Elevated cerebrospinal fluid lactate concentrations in patients
with bipolar disorder and schizophrenia: Implications for themitochon-
drial dysfunction hypothesis. Biol Psychiatry 65:489–494.
3. Holmes E, Tsang TM,Huang JT, Leweke FM, KoetheD, Gerth CW, et al. (2006):
Metabolic profiling of CSF: Evidence that early intervention may impact on
diseaseprogressionandoutcome inschizophrenia.PLoSMed3:e327.
www.sobp.org/journal
77
7
1014 BIOL PSYCHIATRY 2012;71:1006–1014 J.M. das Neves Duarte et al.74. Hatano T, Ohnuma T, Sakai Y, Shibata N, Maeshima H, Hanzawa R, et al.
(2010): Plasma alanine levels increase in patients with schizophrenia as
their clinical symptoms improve-Results from the Juntendo University
Schizophrenia Projects (JUSP). Psychiatry Res 177:27–31.
5. De Graaf-Peters VB, Hadders-Algra M (2006): Ontogeny of the human
nervous system: What is happening when? Early Hum Dev 82:257–266.
76. Farr SA, Poon HF, Dogrukol-Ak D, Drake J, Banks WA, Eyerman E, et al.
(2003): The antioxidants alpha-lipoic acid and N-acetylcysteine reverse
memory impairment and brain oxidative stress in aged SAMP8 mice.
J Neurochem 84:1173–1183.
7
www.sobp.org/journal7. Lanté F, Meunier J, Guiramand J, De Jesus Ferreira MC, Cambonie G
Aimar R, et al. (2008): Late N-acetylcysteine treatment prevents the
deficits induced in the offspring of dams exposed to an immune stress
during gestation. Hippocampus 18:602–609.
8. Izzotti A, BalanskyRM,CamoiranoA, Cartiglia C, LongobardiM, TampaE,
et al. (2003): Birth-related genomic and transcriptional changes in
mouse lung modulation by transplacental N-acetylcysteine. Mutat Res
544:441–449.
9. Schuller-Levis GB, Park E (2003): Taurine: New implications for an old
amino acid. FEMS Microbiol Lett 226:195–202.
